This week, we have an awesome episode where I’ve had the honor and privilege to talk with Ken Epstein CCO and Cofounder at Cannformatics about a premier quantitative study with autistics and how to best prescribe cannabis for them.
Most of what we know to date about cannabis has been case-based qualitative doctor and patient accounts. This breakthrough study quantifies all that, not only helping doctors better prescribe, but also helping doctors dial in the right dosage at a faster time than what has mostly been trial and error to this date.
The paper is being published on December 7 in the scientific peer-reviewed journal Cannabis and Endocannabinoid Research. And the name of the paper is:
“Cannabis-Responsive biomarkers: A pharmacometabolomics based application to evaluate the impact of medical cannabis treatment on children with ASD”
If people have questions they can email Cannformatics at email@example.com.